Impact of insulin-like growth factors and binding proteins on gestational diabetes and fetal growth

Gestational diabetes (GDM) is a common pregnancy complication that can affect the long-term health of both mother and baby. This project seeks to better understand why some individuals develop GDM by examining the role of insulin-like growth factor (IGF) proteins in regulating blood sugar levels during pregnancy. Led by Dr. Marie-France Hivert and Dr. Camille Powe, this study brings together collaborators from MassGeneral Hospital, Northwestern University, Cedars-Sinai Medical Center, and Université de Sherbrooke. Earlier research from this investigative team identified a placental protein called IGFBP1 as a potential regulator of maternal glucose metabolism. Building on this effort, the project will evaluate how IGFBP1 and related proteins influence insulin resistance, gestational diabetes, fetal growth, and newborn health outcomes.

The study combines data from three large human pregnancy cohorts, two international genomics consortia , and one mouse model of GDM to determine whether IGFBP1 treatment impacts maternal glycemic regulation. By improving understanding of the biological mechanisms that contribute to GDM, this work will support the development of more precise strategies for predicting, preventing, and treating high-risk forms of GDM, and ultimately support healthier pregnancies and better long-term health for both mothers and children.